David Pfister, chief of the Head and Neck Service at Memorial Sloan Kettering, has decided to step down from this role after more than 20 years of leadership. He will remain in the position until a successor has been selected.
Results from the LUX-Head & Neck 1 study showed that afatinib significantly delayed tumor growth compared to chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20 percent.
